Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.

doi:10.1111/cas.70431

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.

Cancer science - 1 Sept 2026

Tanaka Takaaki, Fujitani Masato, Taoka Masataka, Shimomura Iwao, Okawa Sachi, Mori Shunta, Kuribayashi Tadahiro, Nishimura Jun, Nishimura Tomoka, Morita Ayako, Hara Naofumi, Ninomiya Kiichiro, Makimoto Go, Higo Hisao, Rai Kammei, Ichihara Eiki, Tomida Shuta, Hotta Katsuyuki, Togashi Yosuke, Maeda Yoshinobu, Kiura Katsuyuki, Katayama Ryohei, Ohashi Kadoaki

Abstract excerpt

Osimertinib is the standard first-line treatment for advanced EGFR-mutant non-small cell lung cancer. However, acquired resistance invariably develops, and identifying novel resistance pathways is clinically important as a substantial portion remains undefined. We used an immunocompetent syngeneic lung cancer mouse model harboring an Egfr exon 19 deletion (mDEL tumors) to establish acquired resistance....

Read the complete abstract on PubMed

Topics

Animals
Afatinib
Pyrimidines
Acrylamides
Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Indoles

Aniline Compounds

ErbB Receptors

Lung Neoplasms

Mice

Humans

Mutation

Cell Line, Tumor

Disease Models, Animal

Protein Kinase Inhibitors

Carcinoma, Non-Small-Cell Lung

Source

Open in PubMed Open full text

Identifiers

PMID: 42226508
DOI: 10.1111/cas.70431
PMCID: PMC13394164

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.PMID 42226508Read ↗

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Acquired resistance mechanisms to osimertinib: The constant battle.Semantic proximity Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Semantic proximity Read ↗

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinibSemantic proximity Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibSemantic proximity Read ↗

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read ↗

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistanceSemantic proximity Read ↗

Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.Semantic proximity Read ↗

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.